- Home
- JL vs KZIA Comparison
JL vs KZIA Comparison
Compare JL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- KZIA
- Stock Information
- Founded
- JL 1985
- KZIA 1994
- Country
- JL Hong Kong
- KZIA Australia
- Employees
- JL N/A
- KZIA N/A
- Industry
- JL
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- KZIA Health Care
- Exchange
- JL NYSE
- KZIA Nasdaq
- Market Cap
- JL 10.1M
- KZIA 18.7M
- IPO Year
- JL 2024
- KZIA 1999
- Fundamental
- Price
- JL $3.03
- KZIA $3.02
- Analyst Decision
- JL
- KZIA Strong Buy
- Analyst Count
- JL 0
- KZIA 1
- Target Price
- JL N/A
- KZIA $20.00
- AVG Volume (30 Days)
- JL 348.7K
- KZIA 84.9K
- Earning Date
- JL 07-31-2024
- KZIA 12-27-2024
- Dividend Yield
- JL N/A
- KZIA N/A
- EPS Growth
- JL N/A
- KZIA N/A
- EPS
- JL 0.26
- KZIA N/A
- Revenue
- JL $28,378,669.00
- KZIA $1,655,324.00
- Revenue This Year
- JL N/A
- KZIA $806.89
- Revenue Next Year
- JL N/A
- KZIA N/A
- P/E Ratio
- JL $11.12
- KZIA N/A
- Revenue Growth
- JL N/A
- KZIA 248000.00
- 52 Week Low
- JL $0.23
- KZIA $1.90
- 52 Week High
- JL $29.95
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- JL 79.30
- KZIA 30.94
- Support Level
- JL $2.64
- KZIA $2.78
- Resistance Level
- JL $3.04
- KZIA $4.20
- Average True Range (ATR)
- JL 0.32
- KZIA 0.55
- MACD
- JL 0.17
- KZIA -0.13
- Stochastic Oscillator
- JL 71.16
- KZIA 9.92
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.